Russian Journal of Skin and Venereal Diseases
ISSN (print): 1560-9588, ISSN (online): 2412-9097 Founders: Izdatelstvo «Meditsyna», «Eco-Vector Publishing Group» Editor-in-Chief: Olisova O.Yu., Doctor of Sc., Full Professor Frequency / Access: 6 issues per year / Hybrid Included in: White List (4th level), Higher Attestation Commission List, RISC
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal exclusive license to first publication. Authors are able to distribute the manuscript and/or the article in accordance with Self-Archiving policy of the journal (see details). The manuscript can be accepted for publication only by decision of the Editor-in-Chief and the Editorial board of the journal in accordance with the Manuscript stelection policy of the journal (see details). Published Article will be distributed in print and electronic version an will be available under subscription with Delayed Open Access or in Immediate Open Access under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). The access model depends on the publisher's decision or is determined by a separate Open Access publishing agreement with the authors. An exclusive license for publication granted by authors allows the publisher to use the article in the following ways: Reproduction of the Article or its sections or parts, as well as the metadata of the Article in any languages, in any material form, including on paper and electronic media, as a separate work in the journal and/or databases (local or in the Internet) of the publisher and/or other persons, at the discretion of the publisher; Distribution of the Article or its sections or parts, as well as the metadata of the Article in any languages, on any medium as part of the journal and/or databases of the publisher or other persons, at the discretion of the publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author; Making the Article or any of its sections or parts, as well as the Article’s metadata in any languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choosing; Granting permission/s for the use of the Article or its sections or parts, as well as its metadata in any languages, to third parties with notice to the Author made by posting relevant information on the journal’s website, without paying remuneration to the Author; Processing the Article (i.e., editing, correcting, annotating, tagging, translating to any languages, typesetting) and using the revised (translated) Article in the aforementioned ways. Other rights not directly transferred to the publisher under this License Agreement, including patent rights to any process, method etc., described by the Authors in the manuscript, as well as trademark rights, are reserved for the Authors. All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Russian Journal of Skin and Venereal Diseases'. - DOWNLOAD the print-version of the License Agreement. READ the details online (tap to see in details) Author’s license agreement (public offer) on the publication of an article in a scholarly journal “Russian Journal of Skin and Venereal Diseases” Eco-Vector, represented by its CEO Evgeniy Schepin and acting on the basis of the Charter (hereinafter referred to as the Publisher), on the one hand, offers an indefinite circle of persons (hereinafter referred to as the Author), and on the other hand, hereinafter jointly referred to as the Parties, to execute this agreement (hereinafter referred to as the Agreement) on the publication of scientific article (hereinafter referred to as the Article) in a scholarly journal “Russian Journal of Skin and Venereal Diseases” (further-the Journal) in accordance with the conditions stated below. I. General Provisions This Agreement, in accordance with clause 2 of Article 437 of the Civil Code of the Russian Federation, is a public offer (hereinafter referred to as the Offer) requiring full and unconditional acceptance (Acceptance), which, in accordance with Article 438 of the Civil Code of the Russian Federation, means the sending by the Author of his/her materials by way of uploading the same to the online electronic system designed to accept manuscripts for consideration, and subsequently posted in the corresponding section of the Journal’s website on the Internet information and telecommunications network (hereinafter referred to as the Internet). In accordance with the current legislation of the Russian Federation regarding the observance of copyright on electronic information resources, all materials found in a website, including submitted and published in electronic journals, may not be reproduced in whole or in part in any form (electronic or printed) without the prior written permission of the Publisher. Prior permission can be given by publishing an article in the open access with Creative Commons license. The journal requires license users to reference the original source, i.e., the publication, if the Author permits use of the public materials in the context of other documents. II. Terms used in the Agreement “Author” refers to an individual (or individuals) whose creative work has led to the creation of the manuscript of a scientific Article, or to a representative of these persons. “Manuscript” is the result of intellectual activity in the form of a scientific work containing text, graphic and numerical data, audiovisual information, program code and other elements submitted by the Author for publication in the Journal; it is also the mean “a draft of an Article submitted by the Author to be published in the Journal”. “Offer” is the current agreement (an offer to the author for the publication of an Article in the Journal). “Publication” is the process of placement of an Article in the Journal. “Article” is the manuscript that has been published in the Journal (after successful selection, editing, type-setting, copyediting, proofreading, translation). “Acceptance of the offer” refers to the full and unconditional acceptance of the offer on the terms specified in paragraph 3 of this agreement (the Author accepts offer by submitting a Manuscript to the Publisher via the online electronic submission system on the Journal’s Internet website). “Journal” is a scientific peer-reviewed periodical registered as a mass media entity in the Roskomnadzor register of the Russian Federation and ISSN-center. “Submission” is an electronic appeal of the Author to the Publisher for the publication of an Article in the Journal by uploading the manuscript and accompanying materials to the online electronic submission system on the Journal’s Internet website). “Publisher” refers to Eco-Vector, which is the Publisher of the journal. Article metadata includes the information that are intended for inclusion in International Scientific Databases and search engines, namely the following: title of the Article; information about each of the Authors (surname and first name; patronymic; place of work with the postal address indicated, contact information (e-mail)); abstract; keywords; thematic rubricator: UDC (Universal Decimal Classification) or other library and bibliographic classification and subject indexes; list of references. “Editorial board” is the creative team that prepares the journal for publication. “Parties” refers to the Author and the Publisher. “Author Guidelines” are the requirements for Articles published in the Journal, posted in the “For authors” section of the Journal’s Internet website. III. Subject of the Agreement (Offer) Under this agreement, the Author grants the Publisher, free of charge for the entire period of validity in accordance with the legislation of the Russian Federation, an exclusive license to use the Article created by the former for publication in the Journal, as well as the rights to use the article in the following ways: Reproduction of the Article or its sections or parts, as well as the metadata of the Article in any languages, in any material form, including on paper and electronic media, as a separate work in Journals and/or databases (local or in the Internet) of the Publisher and/or other persons, at the discretion of the Publisher; Distribution of the Article or its sections or parts, as well as the metadata of the Article in any languages, on any medium as part of the Journal and/or databases of the Publisher or other persons, at the discretion of the Publisher, or as an independent work around the world whether on Open-Access terms or for a fee without remuneration to the Author; Making the Article or any of its sections or parts, as well as the Article’s metadata in any languages, publicly available in such a way that any person can access the Article from any place, including via the Internet, and at any time of their own choosing; Granting permission/s for the use of the Article or its sections or parts, as well as its metadata in any languages, to third parties with notice to the Author made by posting relevant information on the Journal’s website, without paying remuneration to the Author; Processing the Article (i.e., editing, correcting, annotating, tagging, translating to any languages, typesetting) and using the revised (translated) Article in the aforementioned ways. Other rights not directly transferred to the Publisher under this Agreement, including patent rights to any process, method etc., described by the Author in the Article, as well as trademark rights, are reserved for the Author. The territory where the rights to the Article are allowed to be used is the whole world. The validity of this Agreement commences only if the manuscript of the Article is accepted for publication in the Journal and only from the moment of sending a notification of acceptance of the Article for publication to the Author from the official e-mail of the Journal. The rights are granted by the Author to the Publisher free of charge; the publication of the Article in the Journal does not entail any financial deductions to the Author. If the Publisher decides to reject the Submission or refuse to publish the Article in the Journal (i.e., retraction of the published Article), this Agreement becomes invalid. The decision to refuse publication will be sent to the Author at the e-mail address specified in the Submission. IV. Rights and Duties of the Parties The Author guarantees that: s/he holds the copyright the exclusive rights to the materials submitted to the Publisher as part of the manuscript of the Article; the rights granted to the Publisher under this agreement have not been previously transferred and will not be transferred to third parties in the future during the duration of the Agreement; the manuscript contains all references to the cited authors and/or publications (materials) provided for under the current copyright legislation; the Author has obtained all the necessary permissions for all information and other materials s/he holds no copyright to and that are used in the manuscript of the Article; the Article manuscript contains only materials permitted to be published in the open press in accordance with the current legislative acts of the Russian Federation, and its publication and distribution will not lead to the disclosure of secret (confidential) information (including state secrets); the Author has informed co-authors about the terms of this Agreement and has received their consent to execute this Agreement under the terms provided for in the Agreement. The Author carries certain obligations under the terms of the Agreement: s/he should prepare and submit the manuscript of the Article in accordance with the Author Guidelines posted on the Journal’s website; the Author should not use an electronic copy of the Article for commercial purposes and in other journal publications without the consent of the Publisher; in the process of preparing a manuscript for publication, the Author is obligated to undertake the following: make corrections to the text of the manuscript that have been marked by the peer-reviewers and accepted by the editorial board, and/or as necessary, upon the request of the Publisher and the editorial board, finalize the manuscript of the Article; revising and proofreading the manuscript of the Article in accordance with the editorial recommendations; suggest only the minimum of corrections to the type-setted (layout) Article. The Author has the following rights and duties: Use preprint or prior-to publication versions of an unpublished Article in the form and content accepted by the Publisher for publication in the Journal. Such prior-to-publish versions can be placed as electronic files on the personal websites of the Author (co-authors) or on the protected external websites of the employers of the Author; however, the Author cannot use the unpublished version(s) for commercial sale or for systematic external distribution by a third party (i.e., post on social media). The author or co-authors must, in turn, carry out certain duties, namely: include the following warning in the prior-to-publish version: “This is prior-to-publish version of the article accepted for publication in (Journal’s name), © Eco-Vector (year)”; provide the corresponding electronic link to the Publisher’s website at https://journals.eco-vector.com/ and/or via the DOI. Copy or transfer a copy of the published Article in whole or in part to colleagues free of charge for their personal or professional use, for the promotion of academic or scientific research, or for informational purposes of the Author’s employer. Use materials from a published Article in a book written by one of the co-authors. Use figures, tables and text excerpts from the Article for his or her (or co-authors’) own training purposes, or to include them in other published works in printed or electronic format by a third party, or to submit them in electronic format on an internal computer network, or on the public website of the Author (co-authors) or his/her employer. Include the Article in educational collections for use in the classroom, either for free distribution to the Author’s (co-authors’) students or in electronic format on a local server for access by students as part of the training course, as well as for internal training programs at the institution of the Author’s employer. The Publisher, for its part, is obliged to: publish the Author’s article in the Journal in printed and electronic form in accordance with the terms of this Agreement; if necessary, as so decided by the Journal’s editorial board, provide the Author with the proofreading of the manuscript and make a reasonable editing; provide to the Author the unlimited access to the final electronic version of the published Article (Version of Record) through the online electronic submission system on the Journal’s Internet website; comply with the Author’s rights as provided for by the current legislation, as well as protect them and take all necessary measures to prevent copyright infringement by third parties. The Publisher has a right to: conduct an expert evaluation of the manuscript (peer-reviewing and editorial evaluation) and invite the Author to make the necessary changes (revisions) to the manuscript; provide editing, copyediting, type-setting, proofreading, tagging, indexation and translation of the Article’s manuscript without altering the main content; in any subsequent authorized use by the Author (and/or other persons) of the Journal and/or Article (including any separate part or fragment thereof), require that a link to the Journal, Publisher, Author or other copyright holders, the title of the Article, the Journal’s volume/issue, and the year of publication be specified in the Journal; post preliminary and/or advertising information about the upcoming publication of the Article in the media and other information sources; make changes to the offer in accordance with the procedure established by the offer. The editorial board of the Journal, headed by the editor-in-chief, has the exclusive rights to select and/or reject materials sent to the Journal editorial office for publications purposes. The manuscript sent by the Author to the Journal editorial office is not subject to return. The editorial board of the Journal does not enter into correspondence about rejection of submissions. In all cases not stipulated and not provided for in this agreement, the parties are obliged to be guided by the relevant current laws of the Russian Federation. V. Acceptance of the Offer and Execution of the Agreement. Terms of the Agreement The Author accepts the Offer by submitting the manuscript on the Article to the Publisher through the electronic manuscript submission system on the Journal's Internet website. Acceptance of the offer by the author creates an Agreement in writing (Articles 438 and 1286.1 of the Civil Code of the Russian Federation) on the terms of the offer. This Agreement is valid for the duration of the exclusive rights to the Article. When transferring (alienating) the exclusive right to the Article by the Author to a third party, this Agreement does not terminate. VI. Procedure for changing and terminating the Agreement The Publisher has the right to unilaterally change the terms of this Agreement, in advance, at least 10 (ten) calendar days before the entry into force of the intended relevant changes, but with notice to the Author through the Journal’s website or by e-mail to the Author’s e-mail address specified in the Author’s Submission. The changes will take effect from the date specified in the relevant notification. If the Author rejects the changes to the terms of this Agreement, s/he has the right to notify the Publisher by sending a written notification through the online manuscripts submission system, making sure that the same is sent to the official e-mail address of the editorial office. This Agreement may be terminated prematurely, either by agreement of the parties at any time, or on other grounds provided for in this Agreement. The Author has the right to unilaterally withdraw from the execution of this Agreement by sending the Publisher a corresponding notification in writing at least 60 (sixty) calendar days in advance before the expected date of publication of the Article in the Journal. Termination of the Agreement for any reason does not release the parties from liability for any violation of the terms of the Agreement that occurred during the validity period. VII. Responsibility The parties are responsible for non-fulfillment or improper fulfillment of their obligations under the Agreement in accordance with the current relevant legislation of the Russian Federation. All information provided by the Author must be reliable. The Author is expected to provide accurate and complete the information to the Publisher. When using false information received from the Author, the Publisher is not responsible for the negative consequences caused by his actions on the basis of the false information provided. With regard to the content of the Article, the Author is solely responsible for compliance with the requirements of the laws of the Russian Federation pertaining to advertising, copyright and related rights’ protection, protection of trademarks and service marks, and the protection of consumer rights. The Publisher does not bear any responsibility under the agreement: for any actions that are a direct or indirect result of Author’s illegal actions; for any loss incurred by the Author, regardless of whether the Publisher could have foreseen the possibility of such losses or not. The Publisher is released from liability for violation of the terms of the Agreement if such violation is caused by force majeure, including actions of state authorities (including the adoption of legal acts), fire, flood, earthquake, other natural disasters, lack of electricity and/or computer network failures, strikes, civil unrest, riots, etc. VIII. Dispute resolution Disputes and disagreements will be resolved by the parties through negotiations, and in case of failure to reach an Agreement they will strive to seek resolution in accordance with the current legislation of the Russian Federation. If there are unresolved disagreements, the parties agree to resolve the disputes in court at the jurisdiction covered by the Publisher’s location in accordance with the current legislation of the Russian Federation. IX. Miscellaneous All notifications, messages, requests, etc. (with the exception of documents that must be sent as originals in accordance with the laws of the Russian Federation) are considered received by the Author if they were transmitted (sent) by the Publisher through the Journal’s website (including by publication), fax, e-mail based on the address specified in the Submission, and other communication channels. The parties recognize the legal force of notifications, messages, requests, etc., transmitted (sent) by the above methods. In the event of claims against the Publisher related to the violation of the exclusive copyright and other intellectual property rights of third parties when creating an article or in connection with the execution of this Agreement by the Author, as well as in connection with the use of the Article by the Publisher in accordance with the Agreement, the author undertakes: To immediately take measures to resolve disputes with third parties soon after receiving Publisher’s notification, and if necessary, enter into legal proceedings on the Publisher’s side and take all appropriate actions needed to exclude the Publisher from the list of defendants; To reimburse the publisher for the legal costs incurred and expenses and losses caused by the application of measures to secure the claim and execute a court decision, and the money paid to a third party for the violation of exclusive copyright and other intellectual property rights, as well as other losses incurred by the Publisher in connection with the Author’s non-compliance with the guarantees provided by them under this Agreement. X. Legal address and details of the Publisher Eco-Vector Address: 191186, St. Petersburg, Aptekarsky Pereulok, 3 letter A, room 1N TIN: 7806423692; KPP: 784101001; OGRN: 1099847039907.
Lewandowsky–Lutz verruciform epidermodysplasia: a brief review and case report
Verruciform (warty) epidermodysplasia (Lewandowsky–Lutz syndrome) is a rare autosomal recessive disease manifested by multiple cutaneous lesions associated with human papillomavirus infection. To date, no more than 500 patients with this form of genodermatosis have been reported worldwide. Hereditary forms of verruciform (warty) epidermodysplasia are caused by inactivating mutations in the TMC6, TMC8, CIB1, RHOH, and IL7 genes in a homozygous or compound heterozygous state. A non-classical variant of hereditary verruciform (warty) epidermodysplasia has also been described; it is associated with primary T-cell immunodeficiency resulting from mutations in the CORO1A, CARMIL2, DCLRE1C, DOCK8, ECM1, GATA2, LCK, MST1, RASGRP1, and TPP2 genes. Acquired verruciform (warty) epidermodysplasia usually develops in patients with secondary immunodeficiency of various origins. The low prevalence and insufficient clinical diagnostic experience explain the lack of standardized therapy protocols and clinical guidelines for verruciform (warty) epidermodysplasia. Several researchers and clinicians have reported treatment of this condition using chemotherapeutic agents, immunomodulators, interferons, retinoids, and other drugs in combination with surgical excision or physical methods of lesion destruction. This article presents a case report of aggressive verruciform (warty) epidermodysplasia without preceding immunodeficiency or alterations in key genes, describing the experience of treating the patient with a retinoid in combination with CO2 laser destruction of cutaneous lesions.
Dermatoscopic methods for diagnosing radiation-induced skin reactions in patients with primary cutaneous lymphomas undergoing total skin electron beam therapy
Background: Timely diagnosis and assessment of radiation-induced skin reactions remain an important challenge in modern medicine. Imaging techniques can help standardize the clinical evaluation of radiation dermatitis. Aim: The work aimed to evaluate dermatoscopic features and confocal microscopy findings in radiation dermatitis among patients with primary cutaneous lymphomas undergoing radiotherapy, with subsequent analysis of the clinical and morphological characteristics of affected skin areas before treatment and at cumulative doses of 6 Gy, 14 Gy, and 30 Gy, based on macroscopic and dermatoscopic imaging of radiation-induced skin reactions for further comparison. Methods: Data from 40 patients at the Granov Russian Scientific Center for Radiology and Surgical Technologies receiving electron beam radiotherapy for primary cutaneous lymphomas were analyzed. As clinical symptoms of radiation-induced skin reactions developed, morphological changes in the affected areas were examined. Dermatoscopic evaluation of skin lesions was performed using a HYPERLINK "https://shop.heine-med.ru/catalog/dermatoskopy/?ysclid=m63jpoace3558532091"Heine Optotechnik (Germany) dermatoscope at tenfold magnification. Confocal spectroscopy was conducted using the VivaScope® 1500 medical device (MAVIG GmbH, Munich, Germany). Instrumental data underwent correlation analysis to identify statistical relationships between dermatoscopic parameters and the severity of radiation-induced skin reactions. Results: Dermatoscopy revealed patterns characteristic of different stages of radiation-induced skin reactions: reticular vascular arrangements in the dermis, brown scaly elements, perifollicular pigmentation, and follicular plugs arranged in rosette-like patterns. Confocal microscopy of radiation dermatitis lesions identified non-stochastic skin changes, including exocytosis (55.3%), spongiosis (63.5%), disorganization of the epidermis (65%), and abnormally structured dermal papillae (85.4%). Low-contrast microvascular cells marking vascular dysfunction in the dermal vascular bed were a specific feature of radiation dermatitis observed regardless of severity. Conclusion: Accurate assessment of skin damage severity can help optimize the management of patients undergoing radiotherapy for primary cutaneous lymphomas. These findings are promising for integrating instrumental evaluation methods into routine clinical practice for early detection of radiation-induced skin changes and predicting disease severity.
Copyright (c) 2025 Eco-Vector https://creativecommons.org/licenses/by-nc-nd/4.0/
Modern approaches to the treatment of psychosomatic disorders associated with chronic dermatoses: a review
Most contemporary studies indicate a high prevalence of psychosomatic disorders in patients with dermatological conditions. This article presents a systematic scientific data review of therapeutic approaches to psychosomatic disorders associated with chronic dermatoses. The review summarizes data from various studies analyzing psychosomatic aspects of psoriasis, acne, alopecia, lichen planus, and vitiligo, including stress-induced mechanisms of their development and progression, the impact of stigmatization on patients’ psycho-emotional state, as well as quality of life. Particular attention is given to nosogenic (secondary) and comorbid psychiatric disorders associated with the underlying dermatological condition, such as anxiety–depressive disorders, social phobia, and hypochondriacal reactions. The rationale for implementing comprehensive therapeutic strategies has been substantiated, including psychopharmacological interventions (selective serotonin reuptake inhibitors, atypical antipsychotics, anxiolytics), cognitive behavioral therapy, and psychoeducational programs. Multidisciplinary approaches to patient management are considered, integrating dermatological treatment with psychotherapeutic and psychopharmacological methods aimed at improving patients’ adaptation. The article also provides updated information on the treatment of chronic dermatoses. The scientific data search was conducted in national and international scientific databases (PubMed, Scopus, MedLine, Embase, Cochrane, Russian State Library, Central Scientific Medical Library of I.M. Sechenov First Moscow State Medical University). According to the scientific data analysis, psychosomatic disorders comorbid with dermatological diseases require timely detection and treatment. Modern approaches to the treatment of psychosomatic disorders associated with skin diseases involve comprehensive therapy encompassing both dermatological care and psychocorrectional components (psychotherapy and psychopharmacotherapy). Social support also plays an important role. The competent use of psychocorrectional methods in combination with traditional dermatological therapy significantly enhances overall treatment efficacy, improves patients’ quality of life, and reduces the frequency of exacerbations of chronic dermatoses.
Possibilities of IPL technology application in the treatment of patients with acne: review and personal clinical experience
High-energy methods for acne treatment, particularly intense pulsed light (IPL), are gaining increasing popularity in dermatology and esthetic medicine. This review analyzes data on the use of IPL in acne therapy. A systematic search of scientific publications over the past 20 years was conducted, focusing on various IPL application strategies and their effects on the main pathogenic mechanisms of acne. The role of IPL in modulating the skin microbiome and immune response is noted. Evidence is presented confirming the effectiveness of IPL both as monotherapy and in combination with systemic and topical medications. The authors’ own clinical experience in using a combination treatment method for the papulopustular form of mild-to-moderate acne in 28 women aged 18 to 45 years, involving a fixed-dose combination drug (adapalene and benzoyl peroxide) along with phototherapy using broad-spectrum non-coherent light (wavelength range 400–1200 nm), demonstrated a significant reduction in the total dermatological symptom severity index by 82.8% and an improvement in the dermatology life quality index by 80.5%, indicating high efficacy and good tolerability of the therapy. The conducted analytical research and clinical experience support the feasibility of combining IPL with systemic and topical therapies for acne treatment and underscore the need for further research aimed at optimizing acne therapy and developing standardized practical guidelines.
Role of integrated hematological biomarkers of systemic inflammation in assessing the effectiveness of anticytokine therapy in patients with psoriasis
Background: Integrated hematological indices are accessible, cost-effective, and objective parameters for monitoring psoriatic inflammation both in everyday clinical practice and scientific research. Aim: The work aimed to study the effect of anticytokine therapy with an IL-17A inhibitor on NLR, PLR, MLR, SII, and SIRI indices in patients with psoriasis of varying severity. Methods: All patients enrolled in the study had systemic inflammation indices (SIRI, MLR, NLR, SII, PLR, and AISI) calculated before treatment and 6 months after therapy with the IL-17A inhibitor (netakimab). The Psoriasis Area and Severity Index (PASI) was used to assess lesion area and severity of skin involvement. Results: The main group included 77 patients with psoriasis: 33 women (42.9%) and 44 men (57.1%), mean age 41.3 ± 13.4 years, mean PASI 10.8 (3.2; 15.3). Of these, 58 patients (75.4%) had only cutaneous manifestations, and 19 (24.6%) had psoriatic arthritis. In accordance with the clinical guidelines of the Ministry of Health of the Russian Federation for the treatment of patients with psoriasis and psoriatic arthritis, a subgroup of patients receiving IL-17A inhibitor therapy was identified. Subgroup 1 included 20 patients with moderate-to-severe psoriasis, and subgroup 2 included 19 patients with psoriatic arthritis. The total observation period was 10 months. No adverse reactions or complications were observed. Almost complete skin clearance (PASI 75) was observed in all patients of the study group 6 months after initiation of therapy. Different diagnostic trends were observed during treatment with netakimab when analyzing SIRI, MLR, NLR, SII, PLR, and AISI in patients of both subgroups. In patients with psoriatic arthritis, MLR, NLR, and PLR indices showed no statistically significant changes during the treatment. SIRI demonstrated significant changes in both subgroups, whereas AISI was significant only in patients with moderate-to-severe psoriasis. The systemic inflammation index SII proved to be less sensitive and demonstrated changes only in patients with skin manifestations of psoriasis (p = 0.030). Conclusion: Integrated hematological indices of systemic inflammation are promising tools for evaluating the effectiveness of anticytokine therapy in patients with severe psoriasis. NLR, MLR, SII, and AISI can be applied to evaluate the decrease in systemic inflammation exclusively during therapy in patients with cutaneous manifestations of psoriasis, whereas SIRI proved to be effective in both patients with cutaneous psoriasis and those with psoriatic arthritis.
Application of artificial intelligence technologies in dermatology
Dermatology represents a field of medicine with extensive potential for analyzing pathological changes directly in the lesion site, which is reflected in the widespread use of morphological studies for diagnosing skin diseases. With the rapid integration of artificial intelligence technologies into medicine, dermatology has once again become a promising area for the testing and implementation of neural network- and machine learning-based methods for practical medical applications. This article provides a review of scientific publications reporting the use of artificial intelligence technologies in dermatology. For this purpose, 120 research studies published between 2020 and 2025 and indexed in the PubMed database were analyzed. The analysis established that artificial intelligence technologies can be used for the differential diagnosis of malignant skin neoplasms. A large number of images is critical for developing artificial intelligence-based platforms for skin melanoma due to the high heterogeneity of both the clinical and morphological presentation of neoplasms. At the same time, in some cases, image augmentation processes may enhance the effectiveness of the developed methods. In addition to neoplasms, machine learning methods have been applied to develop differential diagnostic algorithms for chronic dermatologic conditions such as atopic dermatitis, psoriasis, alopecia areata, rosacea, and acne. Along with clinical applications, the use of artificial intelligence in dermatology education has also been reported. At the same time, the use of artificial intelligence raises patients’ concerns regarding ethical issues as well as the accuracy of diagnostic and therapeutic strategies; therefore, patients currently view these technologies primarily as complementary to physicians' work.
Retinoids in dermatology: from structure to clinical application
Vitamin A belongs to the group of essential fat-soluble vitamins that are not synthesized in the human body and are supplied with food. The primary function of vitamin A metabolites is to regulate cell growth and differentiation during ontogenesis and in the postnatal period. The widespread use of retinoids in dermatology is attributed to their ability to regulate the growth activity and differentiation of keratinocytes and epithelial cells of the sweat and sebaceous glands. To date, pharmaceutical companies continue to work on improving retinoid molecules to enhance their clinical efficacy and reduce the risk of adverse events. At the same time, the clinical era of retinoids is still at an early stage of development, with research in vitamin A biochemistry significantly outpacing the therapeutic applications of its derivatives. This article focuses on the analysis of the structure, functioning, and biological significance of retinoic receptors in cellular signaling. It examines receptor mechanisms, including classification, mechanisms of interaction with ligand molecules, and factors influencing their activity. The main receptor groups, their molecular characteristics, and intracellular signaling mechanisms triggered by synthetic vitamin A derivatives are described in detail. Special attention is given to receptor activation and desensitization processes, which play a pivotal role in regulating physiological processes. The molecular mechanisms underlying receptor activity, including conformational changes, phosphorylation, and interactions with intracellular signaling proteins, are discussed.
Effectiveness of low-temperature argon plasma in the treatment of dermatological diseases: a review
This review systematically summarizes and critically analyzes current evidence on the use of low-temperature atmospheric plasma in dermatology, focusing on its multimodal mechanisms of action and clinical efficacy. Unlike previous studies that examined individual effects of plasma, this review provides an integrative perspective on low-temperature atmospheric plasma as a therapeutic platform combining antimicrobial, regenerative, and immunomodulatory properties. Special attention is given to the paradoxical selectivity of low-temperature atmospheric plasma—its ability to stimulate the regeneration of normal tissues and simultaneously inducing apoptosis in pathologically altered cells. The article provides an analysis of clinical studies on the use of low-temperature atmospheric plasma in various dermatological conditions (psoriasis, acne, atopic dermatitis, vitiligo, pyoderma gangrenosum), confirming the therapeutic efficacy of the method without significant adverse effects. For the first time, low-temperature atmospheric plasma is considered in the context of skin microbiome modulation, introducing the concept of using this method not only for the elimination of pathogens but also for the restoration of microbial balance. A fundamentally novel aspect is the analysis of low-temperature atmospheric plasma for transdermal drug delivery through the effect of transient changes in cell membrane permeability. The review also highlights current limitations in standardizing plasma treatment parameters and underscores the need for large-scale randomized studies with the aim to develop personalized treatment protocols. This work provides a theoretical foundation for further research into low-temperature atmospheric plasma as a promising alternative to traditional therapeutic methods in dermatology.
Filaggrin: a key to understanding and treating atopic dermatitis
Atopic dermatitis is a chronic inflammatory genetically determined skin disease characterized by high prevalence and a significant negative impact on patients’ quality of life. Impairment of the skin barrier in atopic dermatitis is closely associated with filaggrin deficiency—a key structural protein of the epidermis. Loss-of-function mutations in the FLG gene are a major genetic risk factor for atopic dermatitis, significantly worsening its course and prognosis. Currently, active research is underway to develop effective methods for restoring filaggrin deficiency, which represents a promising approach in the therapy of atopic dermatitis. This article provides a systematic scientific data analysis in the PubMed, Google Scholar, and ClinicalTrials.gov databases to identify modern approaches to restoring the skin barrier in atopic dermatitis by targeting filaggrin and its metabolism. The following promising strategies for targeting filaggrin have been identified: direct replacement therapy with recombinant forms of filaggrin, the use of metabolites (L-histidine, cis-urocanic acid), plant extracts, and mechanical stimulation methods. These approaches demonstrate the potential to improve skin barrier function and reduce inflammation; however, further studies are needed to confirm their clinical efficacy and clarify mechanisms of action. Modern strategies for correcting filaggrin deficiency hold significant therapeutic potential for atopic dermatitis but require further research, including at the molecular and clinical levels, to enable their integration into clinical practice.
Isotretinoin Lidose in clinical practice
Background: Systemic isotretinoin is recommended for the treatment of moderate to severe acne. The specialized Lidose modified-release technology has improved isotretinoin absorption in the gastrointestinal tract, increasing its bioavailability by 20%, thereby allowing a 20% dose reduction without compromising therapeutic efficacy. Aim: The work aimed to estimate the clinical outcomes of isotretinoin Lidose in the treatment of moderate to severe acne. Methods: A retrospective, uncontrolled, single-center study analyzed 2477 cases of systemic isotretinoin prescription in patients with moderate to severe acne, including 1912 women (77.2%) and 565 men (22.8%), with a mean age of 22.7 years; 290 patients (11.7%) had comorbidities. The daily therapeutic dose was calculated based on 0.4–0.8 mg/kg body weight, with a cumulative dose of 100–150 mg/kg. All patients underwent laboratory testing (complete blood count and biochemistry) before treatment, at 3 months, and at the end of therapy. For one month before systemic isotretinoin treatment, throughout the entire treatment course, and for one month after completion, female patients were advised to use at least one (preferably two) effective contraceptive method, including barrier contraception. Results: After 6–12 months, all patients achieved complete clinical remission. By the end of therapy, skin oiliness and comedones disappeared, inflammatory lesions completely resolved, and skin texture became even. Among adverse events, cheilitis and xerosis were most frequently observed by weeks 2–3 and were successfully managed with moisturizers and lip balms. Transient elevations in transaminases and total cholesterol (within 10% of the normal range) were observed in 3.4% of cases, not requiring dose adjustment. Conclusion: Systemic isotretinoin administration for moderate to severe acne allows achieving long-term clinical remission, which leads to a positive effect in preventing acne-related emotional distress. Retrospective analysis of isotretinoin Lidose use in clinical practice confirms not only its good tolerability but also its high efficacy in the treatment of moderate to severe acne.
Autoimmune pemphigus: diagnostic challenges, interdisciplinary interaction, and therapeutic errors
Patient safety is a fundamental principle in the provision of medical care. In the Russian Federation, continuous efforts are undertaken to reduce the number of adverse events, including through systematic analysis of medical errors and undesirable incidents. To illustrate these issues, the article presents four clinical cases of patients with various forms of acantholytic pemphigus. Particular attention is given to the young age of the patients and the clinical course of specific forms of acantholytic pemphigus. The paper discusses shortcomings in medical care, including violations of differential diagnostic algorithms, lack of interdisciplinary continuity, and therapeutic strategy failures. It is reported that diagnostic and therapeutic errors contribute to a more severe course of dermatosis and the transformation of one pemphigus form into another. Timely diagnosis of pemphigus, which belongs to the group of autoimmune bullous dermatoses, is a crucial step in patient management and prevents progression of autoimmune forms in the absence of pathogenetic therapy. Diagnostic criteria include medical history, clinical presentation, cytological examination for acantholytic cells from the base of mucosal and/or skin erosions, histopathological examination of skin biopsy samples from lesions (including direct immunofluorescence methods), and/or indirect immunofluorescence testing of serum to detect IgG and IgA autoantibodies. The article emphasizes the importance of adherence to clinical guidelines, increasing awareness among physicians of related specialties about current features of bullous dermatoses, and improving coordination among specialists from different disciplines. Addressing these issues will improve the quality of medical care and enhance patient safety.
The circadian rhythm is a 24-hour periodic cycle determined by the Earth’s rotation that modulates the behavior, physiology, and metabolism of all living organisms on our planet. The system that controls the circadian rhythm is known as the circadian clock. The mechanism of the circadian clock plays a crucial role in organismal development and functioning. For a long time, circadian clocks operated normally, being dependent on the alternation of light and darkness; however, lifestyle changes (artificial lighting, electronic devices, mobile phones, television, long-distance flights, etc.) have profoundly affected circadian rhythms. The resulting disruptions have led to health problems considered significant in the development of a number of diseases (malignant tumors, cardiovascular diseases, metabolic disorders, obesity, immune dysfunction). In the skin, circadian rhythms are reflected in daily changes in transepidermal water loss, permeability and microcirculatory function, pruritus intensity, sleep–wake cycle, and the activity of the innate and adaptive immune systems. At the cellular level, the circadian rhythm regulates the mitotic cell cycle, keratinocyte differentiation timing, and many other processes. In atopic dermatitis, a vicious cycle exists: pruritus worsens sleep quality, leading to chronic stress, thereby disrupting the sleep–wake circadian rhythm; in turn, sleep deprivation, poor sleep quality, and chronic stress aggravate pruritus. These processes trigger exacerbations of atopic dermatitis, in which both pruritus and poor sleep quality intensify, significantly impairing the rhythmic functioning of the whole body and the skin in particular. Recognizing the importance of circadian skin functions and the consequences of their disruption allows physicians to optimize therapy and maximize efficacy of prescribed treatment. Many topical agents may provide greater benefit if circadian rhythms are taken into account, whereas lower doses or less potent formulations could be sufficient.
Therapeutic potential of prostaglandins in dermatology: focus on vitiligo
This article presents an analysis of the therapeutic potential of prostaglandins in dermatology, with an emphasis on their application in vitiligo. Prostaglandins are a group of low-molecular-weight lipid eicosanoids capable of regulating numerous physiological processes, including renal function, platelet aggregation, neurotransmitter release, and immune system activity, as well as influencing the skin, gastrointestinal tract, and reproductive system. The ubiquitous presence of prostaglandins in body tissues and their involvement in the regulation of inflammatory, regenerative, and proliferative processes make these molecules a promising subject for dermatological research. The therapeutic potential of prostaglandins in dermatology extends far beyond their initial indications. Due to their unique properties, prostaglandins exert a complex effect: on the one hand, they activate melanocytes and stimulate melanogenesis; on the other hand, they modulate immune responses by suppressing autoimmune reactions. This article provides a detailed examination of the mechanisms of action of prostaglandins, including their role in inflammation regulation and their interaction with receptors in the skin. The advantages of prostaglandins in combination therapy for vitiligo are discussed, particularly in conjunction with phototherapy, microneedling, and laser-based methods. The article presents data demonstrating the high efficacy of prostaglandins in treating vitiligo, especially in resistant forms of the disease. The authors emphasize that prostaglandin-based therapy may significantly enhance vitiligo treatment outcomes by increasing repigmentation stability and providing more sustained results. The article also highlights the need for further research to optimize dosing regimens, treatment protocols, and duration of prostaglandin therapy. This review article is based on a systematic search of scientific data (original research, clinical studies, reviews, and guidelines) reflecting current insights into the role of prostaglandins in dermatology and their therapeutic potential in vitiligo over 1987 to 2025 from PubMed, Scopus, Web of Science, and eLibrary.ru.
Chronicles of A.I. Pospelov Moscow Society of Dermatovenerologists and Cosmetologists (MSDС founded on October 4, 1891). Bulletin of the MSDС No. 1161
The 1161st meeting of the A.I. Pospelov Moscow Society of Dermatovenerologists and Cosmetologists was held on February 18, 2025. The meeting, which included both clinical and scientific sections, took place in person in the conference hall of the V.A. Rakhmanov Clinic of Skin and Venereal Diseases (Sechenov University). A total of 110 participants attended. Nine membership applications were submitted to the Society—all from residents and staff members of the Department of Dermatovenereology at the N.I. Pirogov Russian National Research Medical University. The clinical section featured a presentation on sarcoidosis with two patient cases, which expanded the general understanding of specific and nonspecific skin lesions. Another case report on subcorneal pustular dermatosis (Sneddon–Wilkinson disease) highlighted the subtleties of differential diagnosis with pustular psoriasis, impetigo, herpes gestationis, acantholytic pemphigus, and other conditions. It was emphasized that clinical presentation and histological examination are decisive in diagnosing this rare, chronic, benign, relapsing neutrophilic pustular dermatosis. The scientific section opened with a report on Alexey I. Pospelov—the founder of the Moscow Scientific Society of Dermatologists and Venereologists and one of the key figures in the development of the Russian dermatological school. Professor Pospelov described oral mucosal involvement in lichen planus and psoriasis, idiopathic skin atrophy, advocated for the use of X-rays in diagnosing syphilitic bone lesions, and predicted their potential for therapeutic use, but also cautioned against adverse effects. He also developed the neurogenic theory of skin diseases and of alopecia areata. Two additional reports in the scientific section addressed clinical manifestations of onychodystrophies and dermatoses associated with diabetes mellitus.
Herpes zoster is a viral disease. Its development is directly related to the reactivation of the human herpesvirus type 3. At certain points in life, 10%–20% of the population is at risk of developing this condition. The likelihood of disease increases significantly in immunocompromised individuals, including those with HIV infection, malignancies, or those who have undergone bone marrow transplantation, or are receiving long-term cytostatic or systemic glucocorticoid therapy. In people living with HIV, herpes zoster occurs 8–15 times more frequently than in the general population. In immunodeficient states, including HIV-associated immunodeficiency, the course of herpes may have distinct features. This photo gallery presents cases of herpes zoster that developed in the setting of HIV infection. In such cases, clinical manifestation typically occurs when CD4+ T-cell counts fall below 400 cells/μL. In patients not receiving antiretroviral therapy, deeper immunosuppression may lead to recurrence. In some patients with low immune status, herpes zoster may appear as a manifestation of immune system reconstitution inflammatory syndrome. The severity and clinical presentation of the disease are largely determined by the degree of immunodeficiency. In HIV-infected individuals, multidermatomal involvement—affecting two or more dermatomes simultaneously—is common. Compared to HIV-negative individuals, the vesicular eruption phase may last more than 10 days, and atypical forms are more frequently observed (e.g., hemorrhagic, ulceronecrotic, verrucous, disseminated, generalized), which may occur in combination and present with more intense and deeper skin lesions. In HIV-infected individuals, localization of lesions in the external auditory canal is associated with a high risk of auditory involvement, whereas localization in the area innervated by the ophthalmic branch of the trigeminal nerve implies a risk of visual impairment. One possible complication is Ramsay Hunt syndrome (characterized by vesicles in the auricular region, ear pain, and facial nerve paresis or paralysis). According to the Russian clinical classification, the first episode of herpes zoster in a person living with HIV may serve as the basis for diagnosing stage 2B (acute HIV infection with secondary diseases) or stage 4A (secondary diseases) depending on the duration of HIV infection. Recurrent or disseminated herpes zoster corresponds to stage 4B. This photo gallery presents various clinical forms and anatomical locations of herpes zoster in patients with HIV infection. The descriptions of the lesions specify their location in accordance with the innervation zones of peripheral sensory nerves. All photographs presented in this article are from the author’s personal archive.